Soleus Capital Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Soleus Capital Management’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$15.8M	Sell	246,353 -275,000	-53%	-$14.3M	0.54%	48
2026 Q1	$25.1M	Sell	521,353 -65,647	-11%	-$2.91M	1.02%	26
2025 Q4	$24.2M	Buy	587,000 +437,000	+291%	+$17.5M	0.89%	33
2025 Q3	$5.82M	Sell	150,000 -104,689	-41%	-$3.4M	0.29%	57
2025 Q2	$7.05M	Sell	254,689 -214,811	-46%	-$5.47M	0.47%	48
2025 Q1	$10.4M	Buy	+469,500	New	+$9.66M	0.75%	35
2024 Q4	–	Sell	-302,500	Closed	-$7.56M	–	97
2024 Q3	$7.56M	Buy	302,500 +102,500	+51%	+$2.5M	0.59%	46
2024 Q2	$3.73M	Buy	+200,000	New	+$3.75M	0.33%	68
2023 Q4	–	Sell	-157,349	Closed	-$2.73M	–	91
2023 Q3	$2.73M	Sell	157,349 -362,291	-70%	-$6.1M	0.25%	65
2023 Q2	$7.32M	Buy	+519,640	New	+$6.95M	0.81%	39

Other funds holding KNSA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

Soleus Capital Management's KNSA Position: Q2 2026 in Review

Soleus Capital Management reduced its Kiniksa Pharmaceuticals (KNSA) stake by 53% in Q2 2026, selling an estimated $14.3M and leaving 246,353 shares worth $15.8M. The position accounts for 0.54% of the portfolio, ranked #48.

Soleus Capital Management first reported a position in KNSA in Q2 2023 and has held it in 10 quarters since. The position peaked at $25.1M in Q1 2026. 267 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

Soleus Capital Management held 246,353 shares of Kiniksa Pharmaceuticals worth $15.8M as of Q2 2026.
Soleus Capital Management sold 275,000 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $14.3M.
Kiniksa Pharmaceuticals made up 0.54% of Soleus Capital Management's portfolio in Q2 2026, its #48 holding.
Soleus Capital Management first reported a position in Kiniksa Pharmaceuticals in Q2 2023 and has held it in 10 quarters since.
Soleus Capital Management's Kiniksa Pharmaceuticals position peaked at $25.1M in Q1 2026.
267 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Soleus Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.